It also increases the ovarian expression of VEGF-A to a significantly lower degree, which prevents the risks of developing OHSS, and this is due to the more moderate stimulatory effect of TP4/2 on ovarian steroidogenesis. Here, VEGFA is linked to ovarian hyperstimulation syndrome.